Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: A prospective study

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Arrieta, Oscar ^a   Michel Ortega, Rosa M ^a   Villanueva Rodríguez, Geraldine ^a   Serna Thomé, Maria G ^a   Flores Estrada, Diana ^a   Diaz Romero, Consuelo ^a   Rodríguez, Cindy M ^a   Martínez, Luis ^b   Sánchez Lara, Karla ^c  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^c LIVER RESEARCH UNIT   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CISPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT; SERUM ALBUMIN;

ADULT; ADVANCED CANCER; ALBUMIN BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BODY MASS; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; FATIGUE; FEMALE; HUMAN; HYPOALBUMINEMIA; INFLAMMATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPHIL; NUTRITIONAL STATUS; PROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTE; WEIGHT REDUCTION; AGED; BLOOD; CYTOLOGY; LUNG TUMOR; MIDDLE AGED;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHOCYTES; MALE; MALNUTRITION; MIDDLE AGED; NUTRITIONAL STATUS; PACLITAXEL; PROSPECTIVE STUDIES; SERUM ALBUMIN;

EID: 77649293757     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-50     Document Type: Article

References (53)

1. Danaei G, Hoorn S, Lopez AD, Murray CJ, Ezzati M. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet 2005, 366(9499):1784-93. 10.1016/S0140-6736(05)67725-2, 16298215.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA: a cancer journal for clinicians 2008, 58(2):71-96. 10.3322/CA.2007.0010, 18287387.
3. Lazcano Ponce EC, Tovar Guzman V, Meneses Gonzalez F, Rascon Pacheco RA, Hernandez Avila M. Trends of lung cancer mortality in Mexico. Archives of medical research 1997, 28(4):565-70.
4. Ginsberg RJ, Vokes EE, Raben A. Cancer of the lung, section 2: non-small cell lung cancer. Cancer: Principles & Practice 1997, 858. Lippincott Williams & Wilkins, De Vita VT, Hellman S, Rosenberg SA, 8.
5. Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R, Ferry DR, Rudd RM, Spiro SG, Cook JE, Trask C, Bessell E, Connolly CK, Tobias J, Souhami RL. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999, 17(10):3188-94.
6. Harper P. Current clinical practices for ovarian cancers. Seminars in oncology 2002, 29(3 Suppl 8):3-6. 10.1053/sonc.2002.33525, 12082646.
7. Seidman AD. Monotherapy options in the management of metastatic breast cancer. Seminars in oncology 2003, 30(2 Suppl 3):6-10.
8. Rinaldi M, Cauchi C, Gridelli C. First line chemotherapy in advanced or metastatic NSCLC. Ann Oncol 2006, 17(Suppl 5):v64-7. 10.1093/annonc/mdj953, 16807466.
9. Vokes EE, Herndon JE, Crawford J, Leopold KA, Perry MC, Miller AA, Green MR. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 2002, 20(20):4191-8. 10.1200/JCO.2002.03.054, 12377962.
10. Rowinsky EK, Donehower RC. Paclitaxel (taxol). The New England journal of medicine 1995, 332(15):1004-14. 10.1056/NEJM199504133321507, 7885406.
11. Eisenhauer EA, Vermorken JB. The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs 1998, 55(1):5-30. 10.2165/00003495-199855010-00002, 9463787.
12. Venook AP, Egorin MJ, Rosner GL, Brown TD, Jahan TM, Batist G, Hohl R, Budman D, Ratain MJ, Kearns CM, Schilsky RL. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol 1998, 16(5):1811-9.
13. Watanabe H, Yamamoto N, Tamura T, Shimoyama T, Hotta K, Inoue A, Sawada M, Akiyama Y, Kusaba H, Nokihara H, Sekine I, Kunitoh H, Ohe Y, Kodama T, Saijo N. Study of paclitaxel and dose escalation of cisplatin in patients with advanced non-small cell lung cancer. Japanese journal of clinical oncology 2003, 33(12):626-30. 10.1093/jjco/hyg116, 14769840.
14. Timmer-Bonte JN, Punt CJ, vd Heijden HF, van Die CE, Bussink J, Beijnen JH, Huitema AD, Tjan-Heijnen VC. Prophylactic G-CSF and antibiotics enable a significant dose-escalation of triplet-chemotherapy in non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2008, 60(2):222-30.
15. Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Annals of neurology 1994, 35(3):304-11. 10.1002/ana.410350310, 7907208.
16. Rowinsky EK, Chaudhry V, Forastiere AA, Sartorius SE, Ettinger DS, Grochow LB, Lubejko BG, Cornblath DR, Donehower RC. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol 1993, 11(10):2010-20.
17. Gordon JN, Green SR, Goggin PM. Cancer cachexia. Qjm 2005, 98(11):779-88. 10.1093/qjmed/hci127, 16214835.
18. McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 2009, 12(3):223-6. 10.1097/MCO.0b013e32832a7902, 19318937.
19. Vassallo JABE. Actualización Ponderada de los Factores de Riesgo del Cáncer. 2003, Montevideo: Comisión Honoraria de Lucha contra el Cáncer.
20. Muscaritoli M, Bossola M, Aversa Z, Bellantone R, Rossi Fanelli F. Prevention and treatment of cancer cachexia: new insights into an old problem. Eur J Cancer 2006, 42(1):31-41. 10.1016/j.ejca.2005.07.026, 16314085.
21. Ottery FD. Cancer cachexia: prevention, early diagnosis, and management. Cancer practice 1994, 2(2):123-31.
22. Lochs H, Dervenis C. Malnutrition--the ignored risk factor. Digestive diseases (Basel, Switzerland) 2003, 21(3):196-7.
23. Bauer J, Capra S, Ferguson M. Use of the scored Patient-Generated Subjective Global Assessment (PG-SGA) as a nutrition assessment tool in patients with cancer. European journal of clinical nutrition 2002, 56(8):779-85. 10.1038/sj.ejcn.1601412, 12122555.
24. Detsky AS, Baker JP, Mendelson RA, Wolman SL, Wesson DE, Jeejeebhoy KN. Evaluating the accuracy of nutritional assessment techniques applied to hospitalized patients: methodology and comparisons. Jpen 1984, 8(2):153-9.
25. Kuzuya M, Kanda S, Koike T, Suzuki Y, Satake S, Iguchi A. Evaluation of Mini-Nutritional Assessment for Japanese frail elderly. Nutrition (Burbank, Los Angeles County, Calif) 2005, 21(4):498-503.
26. Laky B, Janda M, Bauer J, Vavra C, Cleghorn G, Obermair A. Malnutrition among gynaecological cancer patients. European journal of clinical nutrition 2007, 61(5):642-6.
27. Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology 2007, 73(3-4):215-20. Epub 2008 Apr 17, 10.1159/000127412, 18424885.
28. Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg 2009, 137(2):425-8. Epub 2008 Aug 29, 10.1016/j.jtcvs.2008.05.046, 19185164.
29. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005, 91(3):181-4. 10.1002/jso.20329, 16118772.
30. Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F, Ghaneh P. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 2009, 197(4):466-72. Epub 2008 Jul 17, 10.1016/j.amjsurg.2007.12.057, 18639229.
31. Sarhill N, Mahmoud F, Walsh D, Nelson KA, Komurcu S, Davis M, LeGrand S, Abdullah O, Rybicki L. Evaluation of nutritional status in advanced metastatic cancer. Support Care Cancer 2003, 11(10):652-9. 10.1007/s00520-003-0486-0, 12920623.
32. Busch E, Verazin G, Antkowiak JG, Driscoll D, Takita H. Pulmonary complications in patients undergoing thoracotomy for lung carcinoma. Chest 1994, 105(3):760-6. 10.1378/chest.105.3.760, 8131538.
33. Bashir Y, Graham TR, Torrance A, Gibson GJ, Corris PA. Nutritional state of patients with lung cancer undergoing thoracotomy. Thorax 1990, 45(3):183-6. 10.1136/thx.45.3.183, 462379, 2109900.
34. McMillan DC. An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc 2008, 67(3):257-62. Epub 2008 May 1, 10.1017/S0029665108007131, 18452641.
35. Fabi A, Barduagni M, Ferraresi V, Cortesi E, Gamucci T, De Marinis F, Saltarelli R, Gabriele A, Pellicciotta M, Ceribelli A, De Marco S, Facciolo F, Cognetti F. The combination of carboplatin and weekly paclitaxel: a safe and active regimen in advanced non small-cell lung cancer patients. A phase I-II study. J Exp Clin Cancer Res 2004, 23(1):25-32.
36. Paal K, Shkarupin A. Paclitaxel binding to the fatty acid-induced conformation of human serum albumin--automated docking studies. Bioorganic & medicinal chemistry 2007, 15(24):7568-75. 10.1016/j.bmc.2007.09.006, 17892938.
37. Kratz F, Ehling G, Kauffmann HM, Unger C. Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin. Human & experimental toxicology 2007, 26(1):19-35. 10.1177/0960327107073825, 17334177.
38. D'Angio RG. Is there a role for albumin administration in nutrition support?. The Annals of pharmacotherapy 1994, 28(4):478-82.
39. Guthrie RD, Hines C. Use of intravenous albumin in the critically ill patient. The American journal of gastroenterology 1991, 86(3):255-63.
40. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 2003, 89(6):1028-30. 10.1038/sj.bjc.6601242, 2376960, 12966420.
41. Holroyde CP, Reichard GA. General metabolic abnormalities in cancer patients: anorexia and cachexia. The Surgical clinics of North America 1986, 66(5):947-56.
42. Wilson DO, Rogers RM, Hoffman RM. Nutrition and chronic lung disease. The American review of respiratory disease 1985, 132(6):1347-65.
43. Morss Dy S. Enteral and Parenteral Nutrition in Terminally Ill Cancer Patients: A Review of the Literature. Am J Hosp Palliat Care 2006, 23:369-77. 10.1177/1049909106292167, 17060304.
44. Casado-Cobo SCR. Dietary interventions in Cancer. Rev Oncol 2004, 6:496-500.
45. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Comparison of aninflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer 2004, 90(9):1704-6. 2409737, 15150622.
46. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to in6lammation. N Engl J Med 1999, 340:448-454. 10.1056/NEJM199902113400607, 9971870.
47. Nakahara Y, Mochiduki Y, Miyamoto Y, Nakahara Y, Katsura Y. Prognostic significance of the lymphocyte-to-neutrophil ratio in percutaneous fine-needle aspiration biopsy specimens of advanced nonsmall cell lung carcinoma. Cancer 2005, 104(6):1271-80. 10.1002/cncr.21290, 16047345.
48. Lissoni P, Brivio F, Fumagalli L, Messina G, Ghezzi V, Frontini L, Giani L, Vaghi M, Adizzoia A, Gardani GS. Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors. Int J Biol Markers 2004, 19(2):135-40.
49. Sung JBG, Joshi M, Bochicchio K, Costas A, Tracy K, Scalea TM. Admission serum albumin is predicitve of outcome in critically ill trauma patients. Am Surg 2004, 70:1099-102.
50. Kuzuya MIS, Enoki H, Okada K, Iguchi A. Is serum albumin a good marker for malnutrition in the physically impaired elderly?. Clin Nutr 2007, 26:84-90. 10.1016/j.clnu.2006.07.009, 16996659.
51. Win TRA, Wells F, Laroche C. The incidence and impact of low body mass index on patients with operable lung cancer. Clin Nutr 2007, 26:440-43. 10.1016/j.clnu.2007.01.009, 17368875.
52. Numeroso F, Barilli AL, Delsignore R. Prevalence and significance of hypoalbuminemia in an internal medicine department. European journal of internal medicine 2008, 19(8):587-91. 10.1016/j.ejim.2007.04.029, 19046723.
53. Evans WK, Nixon DW, Daly JM, Ellenberg SS, Gardner L, Wolfe E, Shepherd FA, Feld R, Gralla R, Fine S. A randomized study of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small-cell lung cancer. J Clin Oncol 1987, 5(1):113-24.